KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2027-02-08
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of oral KPT-9274 for the treatment of
patients with relapsed or refractory acute myeloid leukemia.